(Q38008607)

26 August 2017

title

Recent developments with live-attenuated recombinant paramyxovirus vaccines (English)

1 reference

26 August 2017

1 reference

Manuel Rosa-Calatrava

series ordinal

3

object named as

Manuel Rosa-Calatrava

1 reference

26 August 2017

4

Guy Boivin

1 reference

26 August 2017

2

Bruno Lina

1 reference

26 August 2017

author name string

Jean-Christophe Le Bayon

series ordinal

1

1 reference

26 August 2017

language of work or name

1 reference

8 May 2012

1 reference

Reviews in Medical Virology

26 August 2017

published in

1 reference

26 August 2017

volume

23

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

15-34

1 reference

The paramyxovirus SV5 small hydrophobic (SH) protein is not essential for virus growth in tissue culture cells

26 August 2017

cites work

1 reference

Ten years of human metapneumovirus research.

21 January 2018

1 reference

Induction of apoptosis by paramyxovirus simian virus 5 lacking a small hydrophobic gene

21 January 2018

1 reference

Function of small hydrophobic proteins of paramyxovirus

21 January 2018

1 reference

Low-pH-induced membrane fusion mediated by human metapneumovirus F protein is a rare, strain-dependent phenomenon

21 January 2018

1 reference

Low-pH triggering of human metapneumovirus fusion: essential residues and importance in entry

21 January 2018

1 reference

Identification of nucleolin as a cellular receptor for human respiratory syncytial virus

21 January 2018

1 reference

Integrin alphavbeta1 promotes infection by human metapneumovirus

21 January 2018

1 reference

Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate

21 January 2018

1 reference

Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo

21 January 2018

1 reference

Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation

21 January 2018

1 reference

Cleavage at the furin consensus sequence RAR/KR(109) and presence of the intervening peptide of the respiratory syncytial virus fusion protein are dispensable for virus replication in cell culture

21 January 2018

1 reference

The structural basis of paramyxovirus invasion

21 January 2018

1 reference

Bimolecular complementation of paramyxovirus fusion and hemagglutinin-neuraminidase proteins enhances fusion: implications for the mechanism of fusion triggering

21 January 2018

1 reference

Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion

21 January 2018

1 reference

Addition of N-glycans in the stalk of the Newcastle disease virus HN protein blocks its interaction with the F protein and prevents fusion

21 January 2018

1 reference

Hemagglutinin-neuraminidase-independent fusion activity of simian virus 5 fusion (F) protein: difference in conformation between fusogenic and nonfusogenic F proteins on the cell surface

21 January 2018

1 reference

Identification of regions on the fusion protein of human parainfluenza virus type 2 which are required for haemagglutinin-neuraminidase proteins to promote cell fusion

21 January 2018

1 reference

A conserved region between the heptad repeats of paramyxovirus fusion proteins is critical for proper F protein folding

21 January 2018

1 reference

Structure of the Newcastle disease virus F protein in the post-fusion conformation

21 January 2018

1 reference

Deletion of human metapneumovirus M2-2 increases mutation frequency and attenuates growth in hamsters

21 January 2018

1 reference

The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription

21 January 2018

1 reference

Nonstructural proteins NS1 and NS2 of bovine respiratory syncytial virus block activation of interferon regulatory factor 3

21 January 2018

1 reference

Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]

21 January 2018

1 reference

The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response

21 January 2018

1 reference

Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.

21 January 2018

1 reference

Population-based incidence of human metapneumovirus infection among hospitalized children

21 January 2018

1 reference

Virologically confirmed population-based burden of hospitalization caused by respiratory syncytial virus, adenovirus, and parainfluenza viruses in children in Hong Kong.

21 January 2018

1 reference

Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000

21 January 2018

1 reference

Parainfluenza virus bronchiolitis. Epidemiology and pathogenesis

21 January 2018

1 reference

Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children

21 January 2018

1 reference

Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children

21 January 2018

1 reference

A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice

21 January 2018

1 reference

Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis

21 January 2018

1 reference

Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants

21 January 2018

1 reference

Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection

21 January 2018

1 reference

Mortality associated with influenza and respiratory syncytial virus in the United States

21 January 2018

1 reference

Possible transmission by fomites of respiratory syncytial virus

21 January 2018

1 reference

Incubation periods of acute respiratory viral infections: a systematic review.

21 January 2018

1 reference

Role of retinoic acid inducible gene-I in human metapneumovirus-induced cellular signalling

21 January 2018

1 reference

Local cytokine response upon respiratory syncytial virus infection.

21 January 2018

1 reference

Differential production of inflammatory cytokines in primary infection with human metapneumovirus and with other common respiratory viruses of infancy

21 January 2018

1 reference

Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity.

21 January 2018

1 reference

Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus

21 January 2018

1 reference

CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection

21 January 2018

1 reference

Respiratory syncytial virus disease: update on treatment and prevention

21 January 2018

1 reference

Parainfluenza virus type 3 infections in hematopoetic stem cell transplant recipients: response to ribavirin therapy

21 January 2018

1 reference

Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome

21 January 2018

1 reference

Immune modulatory activity of ribavirin for serious human metapneumovirus disease: early i.v. therapy may improve outcomes in immunosuppressed SCT recipients.

21 January 2018

1 reference

Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro

21 January 2018

1 reference

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

21 January 2018

1 reference

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

21 January 2018

1 reference

Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.

21 January 2018

1 reference

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

21 January 2018

1 reference

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

21 January 2018

1 reference

A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years

21 January 2018

1 reference

Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model.

21 January 2018

1 reference

Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus

21 January 2018

1 reference

Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

21 January 2018

1 reference

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

21 January 2018

1 reference

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

21 January 2018

1 reference

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

21 January 2018

1 reference

Immunopathogenesis of vaccine-enhanced RSV disease.

21 January 2018

1 reference

A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines

21 January 2018

1 reference

Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease

21 January 2018

1 reference

Enhanced pulmonary pathology in cotton rats upon challenge after immunization with inactivated parainfluenza virus 3 vaccines

21 January 2018

1 reference

Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus

21 January 2018

1 reference

Human metapneumovirus: enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged.

21 January 2018

1 reference

Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection

21 January 2018

1 reference

Studies on an attenuated measles-virus vaccine. VIII. General summary and evaluation of the results of vaccine

21 January 2018

1 reference

Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation

21 January 2018

1 reference

Combined Live Measles, Mumps, and Rubella Virus Vaccines

21 January 2018

1 reference

Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.

21 January 2018

1 reference

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

21 January 2018

1 reference

Effectiveness of maternal influenza immunization in mothers and infants

21 January 2018

1 reference

Protection of cotton rats against human parainfluenza virus type 3 by vaccination with a chimeric FHN subunit glycoprotein

21 January 2018

1 reference

Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3.

21 January 2018

1 reference

Comparison of soluble and secreted forms of human parainfluenza virus type 3 glycoproteins expressed from mammalian and insect cells as subunit vaccines

21 January 2018

1 reference

Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats

21 January 2018

1 reference

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

21 January 2018

1 reference

Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques

21 January 2018

1 reference

Reverse genetics of negative-stranded RNA viruses: a global perspective

21 January 2018

1 reference

Partial characterization of a Sendai virus replication promoter and the rule of six.

21 January 2018

1 reference

Minimum protein requirements for transcription and RNA replication of a minigenome of human parainfluenza virus type 3 and evaluation of the rule of six.

21 January 2018

1 reference

Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys

21 January 2018

1 reference

Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates

21 January 2018

1 reference

Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes

21 January 2018

1 reference

Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates

21 January 2018

1 reference

Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.

21 January 2018

1 reference

Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses

21 January 2018

1 reference

Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys

21 January 2018

1 reference

Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants

21 January 2018

1 reference

A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy

21 January 2018

1 reference

Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates

21 January 2018

1 reference

Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector

21 January 2018

1 reference

Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys

21 January 2018

1 reference

Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity

21 January 2018

1 reference

Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.

21 January 2018

1 reference

Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children

21 January 2018

1 reference

Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children

21 January 2018

1 reference

Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults

21 January 2018

1 reference

Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

21 January 2018

1 reference

Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B

21 January 2018

1 reference

Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections

21 January 2018

1 reference

Sendai virus-based RSV vaccine protects African green monkeys from RSV infection

21 January 2018

1 reference

An outbreak of conjunctivitis due to Newcastle disease virus (NDV) occurring in poultry workers

21 January 2018

1 reference

Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates

21 January 2018

1 reference

Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans

21 January 2018

1 reference

Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees

21 January 2018

1 reference

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants

21 January 2018

1 reference

The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans

21 January 2018

1 reference

The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines

21 January 2018

1 reference

Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates

21 January 2018

1 reference

Human metapneumovirus glycoprotein G inhibits innate immune responses

21 January 2018

1 reference

Soluble recombinant human metapneumovirus G protein is immunogenic but not protective

21 January 2018

1 reference

Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo

21 January 2018

1 reference

Frequent frameshift and point mutations in the SH gene of human metapneumovirus passaged in vitro

21 January 2018

1 reference

Progress in respiratory virus vaccine development

21 January 2018

1 reference

A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys

21 January 2018

1 reference

Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector

21 January 2018

1 reference

AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats

21 January 2018

1 reference

Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins

21 January 2018

1 reference

Assembly and biological and immunological properties of Newcastle disease virus-like particles

21 January 2018

1 reference

Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice

21 January 2018

1 reference

Progress in respiratory virus vaccine development.

21 January 2018

1 reference

Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine.

21 January 2018

1 reference

Mode of action of adjuvants: implications for vaccine safety and design.

21 January 2018

1 reference

Progress in the development of human parainfluenza virus vaccines

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/RMV.1717

1 reference

26 August 2017

1 reference